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IMPORTANCE Many patients with coronavirus disease 2019 (COVID-19) are critically ill and
require care in the intensive care unit (ICU).
OBJECTIVE To evaluate the independent risk factors associated with mortality of patients with
COVID-19 requiring treatment in ICUs in the Lombardy region of Italy.
DESIGN, SETTING, AND PARTICIPANTS This retrospective, observational cohort study included
3988 consecutive critically ill patients with laboratory-confirmed COVID-19 referred for
ICU admission to the coordinating center (Fondazione IRCCS [Istituto di Ricovero e Cura a
Carattere Scientifico] Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19
Lombardy ICU Network from February 20 to April 22, 2020. Infection with severe acute
respiratory syndrome coronavirus 2 was confirmed by real-time reverse transcriptase–
polymerase chain reaction assay of nasopharyngeal swabs. Follow-up was completed on
May 30, 2020.
EXPOSURES Baseline characteristics, comorbidities, long-termmedications, and ventilatory
support at ICU admission.
MAIN OUTCOMES ANDMEASURES Time to death in days from ICU admission to hospital
discharge. The independent risk factors associated with mortality were evaluated with
a multivariable Cox proportional hazards regression.
RESULTS Of the 3988 patients included in this cohort study, themedian age was 63
(interquartile range [IQR] 56-69) years; 3188 (79.9%; 95% CI, 78.7%-81.1%) were men, and
1998 of 3300 (60.5%; 95% CI, 58.9%-62.2%) had at least 1 comorbidity. At ICU admission,
2929 patients (87.3%; 95% CI, 86.1%-88.4%) required invasive mechanical ventilation (IMV).
Themedian follow-up was 44 (95% CI, 40-47; IQR, 11-69; range, 0-100) days; median time
from symptoms onset to ICU admission was 10 (95% CI, 9-10; IQR, 6-14) days; median length
of ICU stay was 12 (95% CI, 12-13; IQR, 6-21) days; andmedian length of IMVwas 10 (95% CI,
10-11; IQR, 6-17) days. Cumulative observation time was 164 305 patient-days. Hospital and
ICUmortality rates were 12 (95% CI, 11-12) and 27 (95% CI, 26-29) per 1000 patients-days,
respectively. In the subgroup of the first 1715 patients, as of May 30, 2020, 865 (50.4%) had
been discharged from the ICU, 836 (48.7%) had died in the ICU, and 14 (0.8%) were still in
the ICU; overall, 915 patients (53.4%) died in the hospital. Independent risk factors associated
with mortality included older age (hazard ratio [HR], 1.75; 95% CI, 1.60-1.92), male sex (HR,
1.57; 95% CI, 1.31-1.88), high fraction of inspired oxygen (FiO2) (HR, 1.14; 95% CI, 1.10-1.19),
high positive end-expiratory pressure (HR, 1.04; 95% CI, 1.01-1.06) or low PaO2:FiO2 ratio (HR,
0.80; 95% CI, 0.74-0.87) on ICU admission, and history of chronic obstructive pulmonary
disease (HR, 1.68; 95% CI, 1.28-2.19), hypercholesterolemia (HR, 1.25; 95% CI, 1.02-1.52), and
type 2 diabetes (HR, 1.18; 95% CI, 1.01-1.39). Nomedication was independently associated
with mortality (angiotensin-converting enzyme inhibitors HR, 1.17; 95% CI, 0.97-1.42;
angiotensin receptor blockers HR, 1.05; 95% CI, 0.85-1.29).
CONCLUSIONS AND RELEVANCE In this retrospective cohort study of critically ill patients
admitted to ICUs in Lombardy, Italy, with laboratory-confirmed COVID-19, most patients
required IMV. Themortality rate and absolute mortality were high.
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A s of June 16, 2020, 8 251 224 severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) infections and445 188 coronavirus disease 2019 (COVID-19)–related
deaths had been reported worldwide.1 Among active cases,
1.6% (54593 of 3 503249) are in severe or critical condition.
Lombardy, a regionofNorthern Italy,was the epicenter of
the first COVID-19outbreak in awestern country.2OnApril 22,
3940 of 69092 laboratory-confirmed cases (5.7%) required
admission to one of the intensive care units (ICUs) of the
COVID-19 Lombardy ICU Network.3 Knowledge of baseline
patient characteristics and risk factors associatedwith ICUand
hospitalmortality is still limited.Male sex, hypertension, car-
diovascular disorders, and type2diabetes are themost preva-
lent comorbidities, and they are associated with a high case
fatality rate.4-11 Theprevalence of chronic obstructive pulmo-
nary disease is typically less than 10%.4,6-8,10-12 It has been
hypothesized that the use of drugs acting on the renin-
angiotensin systemmay be associated with the course of the
disease, because SARS-CoV-2 enters the host cells by binding
to the angiotensin-converting enzyme 2 (ACE2).6,13-17
Acute respiratory distress syndrome has been diagnosed
in40%to96%6-8,12,18 of thepatients admitted to the ICU.Need
for invasive mechanical ventilation (IMV) varied widely be-
tween thedifferent case seriesbut is invariablyassociatedwith
high mortality,4-6,8,10,18,19 with ICU mortality ranging from
16% to 78%.7-9,11,12,18-20 A prior study from the COVID-19
Lombardy ICU Network5 reported an ICU mortality of 25.6%
(15%aged 14-63years; 36%aged64-91 years); however, 58.2%
of patients were still in the ICU at the end of follow-up.
We herein report ICU and hospital outcomes of the first
3988 patients critically ill with COVID-19 referred to the
Coordinating Center (Fondazione IRCCS [Istituto di Ricovero
e Cura a Carattere Scientifico] Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy) of the COVID-19 Lombardy ICU
Network.2,5 Some data from the first 1591 patients have been
previously reported.5 We describe the baseline characteris-
tics of the patients, comorbidities, concomitant treatments at
the time of hospital admission, mode and setting of ventila-
tory support, and the associationof these characteristicswith
time to death.
Methods
Patients and Data Collection
The institutional ethicsboardofFondazione IRCCSCa’Granda
OspedaleMaggiorePoliclinico,Milan, approved this studyand
waived the need for informed consent from individual pa-
tientsowing to the retrospectivenatureof thestudy.This study
followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline.
This retrospective, observational study enrolled all
consecutive patients with confirmed SARS-CoV-2 infection
admitted to one of the Network ICUs from February 20 to
April 22, 2020. To the best of our knowledge, all the critically
ill patients requiring ICU admission in Lombardy have been
referred to the Regional Coordinating Center. Laboratory
confirmation of SARS-CoV-2 was defined as a positive result
of real-time reverse transcriptase–polymerase chain reaction
assay of nasal and pharyngeal swabs and, in selected cases,
confirmation with reverse transcriptase–polymerase chain
reaction assay from lower respiratory tract aspirates.
The staff of the Regional Coordinating Center contacted
each ICU of the Network daily by telephone and recorded on
an electronicworksheet the demographic and clinical patient
data. The following variables within the first 24 hours of ICU
admission were recorded: age, sex, mode of respiratory sup-
port (IMV, noninvasivemechanical ventilation [NIV], oxygen
mask), level of positive end-expiratory pressure (PEEP), frac-
tion of inspired oxygen (FiO2), arterial partial pressure of oxy-
gen (PaO2), PaO2:FiO2 ratio, use of extracorporeal membrane
oxygenation, and prone positioning. Preexisting comorbidi-
ties, long-term use of medications, and date of symptom
onset were retrieved from the Regional Health System
Database, which is based on the prescription of the general
practitioners. The definitions of home intake of long-term
medications and of each comorbidity, derived from
the Regional Database, are presented in the eMethods in the
Supplement.
The ICU and hospital outcomes of each patient were
recorded onMay 30, 2020. The interval from symptomonset
to ICU admission, length of ICU stay, rate of reintubation, and
rate of readmission to ICU were also evaluated.
Statistical Analysis
Categorical variables are reported as frequencies (percent-
ages with 95% CIs) and continuous variables as means
(with SDs) or medians (with interquartile ranges [IQRs] and
95%CIs)according todistribution.Groupswerecomparedwith
Wilcoxon rank sum tests with Benjamini and Hochberg cor-
rection for multiple comparison according to data distribu-
tion for continuous variables, andwithPearson χ2 test (Fisher
exact test where appropriate) for categorical variables.
Life status was determined for all patients as of May 30,
2020, from the Regional Health Authority. Time-to-event
techniques were used to analyze survival from ICU admis-
sion. Overall mortality rate was calculated per 1000 patient-
days. The ICU and hospital mortality rates were calculated
Key Points
Question What are the risk factors associated with mortality
among critically ill patients with laboratory-confirmed coronavirus
disease 2019 admitted to intensive care units in Lombardy, Italy?
Findings In this cohort study that involved 3988 critically ill
patients admitted from February 20 to April 22, 2020, the hospital
mortality rate as of May 30was 12 per 1000 patient-days after
a median observation time of 70 days. In the subgroup of the first
1715 patients, 865 (50.4%) had been discharged from the intensive
care unit, 836 (48.7%) had died in the intensive care unit, and
14 (0.8%) were still in the intensive care unit; 915 patients died
in the hospital for overall hospital mortality of (53.4%).
Meaning This study found that most critically ill patients with
coronavirus disease 2019 in the intensive care unit required
invasive mechanical ventilation, andmortality rate and absolute
mortality rate were high.
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analogously, taking into account only time until ICU (or
hospital) discharge.
Days from ICU admission to death (event) or May 30,
2020 (censoring), constituted the time of analysis. At the
time of censoring, patients might be alive in the ICU, alive in
hospital, or alive and discharged. For patients readmitted to
the ICU after discharge, the first ICU admission was consid-
ered in the analysis.
We calculated Kaplan-Meier survival estimates and used
the log-rank test to compare groups in terms of survival. The
association of risk factors with time to death was assessed in
univariable and multivariable Cox proportional hazards re-
gression models. The proportional hazard assumption was
tested by plotting the Nelson-Aalen cumulative hazard func-
tion and Schoenfeld residuals test.21
Fourmultivariablemodelsweredevelopedfordemograph-
ics (model 1), comorbidities (model 2), drugs (model 3), and
respiratory parameters (model 4) using variables strongly as-
sociated with mortality at univariable analysis, known from
previous literature tobe strongly associatedwithoutcomeand
not collinear.Weused theAkaike informationcriterion tocom-
paredifferent regressionmodels and select themost parsimo-
nious model.
The finalmodel included independent factors frommod-
els 1 to 3 only (model 4 was run on a subset of data owing to
missing data), with no further selection. The number of
patientswithmissing datawere 0 for outcomes, 82 for drugs,
688forcomorbidities, 1053 forPaO2,984forFiO2, 1074forPaO2:
FiO2 ratio, and958 for PEEPon ICUadmission. Detailed infor-
mation about missing data are reported in eFigure 1 in the
Supplement.
A subgroup analysis was performed on the first 1715
patients, most of whom were included in a prior report.6 As
of May 30, 2020, 14 (0.8%) of these patients were still in
the ICU, and 865 (50.4%) had been discharged from the ICU.
A second subgroup analysis was performed on the 1643
patients with hypertension to explore the potential role of
ACE inhibitors and antihypertensive drugs in this subset.
A third subgroup analysis was performed on the 350 patients
treatedwithNIV in the ICUtoassess theassociationofNIVwith
patientoutcomes.Rsoftware,version4.0 (RCoreTeam,2020),
and STATA computer software, version 16.0 (StataCorp LLC),
were used for data analysis. Two-sided P < .05 indicated
significance.
Results
Description of the Cohort
From a population of 4209 patients admitted to ICUs in
Lombardy with suspected SARS-CoV-2 infection to April 22,
2020, we excluded 127 patients with negative reverse tran-
scriptase–polymerase chain reaction findings for SARS-
CoV-2and94patientsmissing results of reverse transcriptase–
polymerase chain reaction for SARS-CoV-2. Data from 3988
patients (median age, 63 [IQR, 56-69] years) were analyzed.
Table 1 showstheassociationsbetweendemographicandbase-
linecharacteristicsandmortality.Mostpatientsweremen(3188
[79.9%; 95% CI, 78.7%-81.1%]), with amedian age of 63 (95%
CI, 62-63; IQR, 55-69) years. Eight hundred patients were
women (20.1%; 95% CI, 18.9%-21.3%]), with a median age
of 64 (95% CI, 63-65; IQR, 57-70) years. Median time from
symptom onset to ICU admission was 10 (95% CI, 9-10; IQR,
6-14) days. One thousand nine hundred and ninety-eight
of 3300 patients (60.5%; 95% CI, 58.9%-62.2%) had at least
1 comorbidity. Hypertension was the most common comor-
bidity (1643 [42.1%; 95% CI, 40.5%-43.6%]), followed by
hypercholesterolemia (545 [16.5%; 95%CI, 15.3%-17.8%]) and
heart disease (533 [16.2%; 95% CI, 14.9%-17.4%]).
Observation Time andMain Outcomes
Cumulative observation time was 164 305 patient-days from
ICU admission to end of follow-up for the 3988 patients
(medianobservation time, 70 [range, 38-112] days; IQR, 61-70
days). After a median follow-up of 69 (IQR, 60-78; range, 38-
100) days, there were 1926 deaths (overall mortality, 48.3%)
for amortality rate of 12 (95%CI, 11-12) per 1000 patient-days
(Figure). There were 1769 ICU deaths (44.3%), for an ICU
mortality rate of 27 (95%CI, 26-29) per 1000 patient-days. At
the time of censoring, 91 patients (2.3%; 95% CI, 1.9%-2.8%)
were still in the ICU, and 2049 (51.4%; 95% CI, 49.8%-52.9%)
had been discharged from the ICU. Among the latter, 1480
patients (37.1%; 95% CI, 35.6%-38.6%) had been discharged
from the hospital and 501 (12.6%; 95% CI, 11.6%-13.6%) were
still hospitalized; the mortality rate after discharge from the
ICU was 2 (95% CI, 1-2) per 1000 patient-days.
Distribution of patients’ outcomes by ICU admission date
is presented in the eFigure 2 in the Supplement. Median ICU
stay was 12 (IQR, 6-21; range, 0-87) days, and themedian du-
rationofmechanical ventilationwas 10 (IQR,6-17; range,0-87)
days. Median length of stay in hospital was 28 (IQR, 15-48;
range, 0-120) days.
Of the 2049 patients discharged from the ICU, 134 (6.5%)
were readmitted to the ICU after discharge. Sixty-four of 3857
patients (1.7%)underwent extracorporealmembraneoxygen-
ation support during the ICU stay, of whom 40 died (62.5%),
13 were discharged home (20.3%), and 11 were still hospital-
ized (17.2%).
At ICUadmission,2929of3355patients (excluding633with
missing data) underwent intubation (87.3%; 95% CI, 86.1%-
88.4%). Three hundred and fifty patients underwent nonin-
vasive respiratory support with NIV (10.4%; 95% CI, 9.4%-
11.5%), which in most cases consisted of continuous positive
air pressure delivered through a helmet or a standard oxygen
mask (76 of 3355 patients [2.3%]).
Univariable Analysis
A 10-year increase in age was significantly associated with
mortality (hazard ratio [HR], 1.86; 95%CI, 1.76-1.96;P < .001).
Patients 64 years or older had significantly decreased sur-
vival probability compared with younger patients (Figure).
Hypertension, hypercholesterolemia, heart disease,
diabetes, malignant neoplasm, chronic obstructive pulmo-
narydisease, chronickidneydisease, andall the studiedmedi-
cations taken at homebefore entering the hospitalwere asso-
ciatedwith increasedmortality atunivariable analysis (Table 1
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Table 1. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of 3988 Patients
With COVID-19 Admitted to the ICU in Lombardy, Italy
Characteristica
No. of
patients
(n = 3988)
No. of
deaths
(n = 1926)
Mortality rate per
1000 patient-days HR (95% CI) P value
Age, y
<56 997 245 4.5 (3.9-5.0) 1 [Reference] NA
56-63 997 416 9.2 (8.3-10.1) 1.91 (1.63-2.24) <.001
64-69 997 562 15.6 (14.3-16.9) 2.98 (2.56-3.46) <.001
>69 997 703 25.2 (23.4-27.1) 4.25 (3.68-4.92) <.001
Men 3188 1580 12.2 (11.6-12.9) 1.22 (1.08-1.37) <.001
Women 800 346 9.9 (8.8-10.9) 0.73 (0.82-0.92) <.001
Comorbidities
None 1302 490 7.7 (7.0-8.4) 0.55 (0.49-0.61) <.001
Hypertension 1643 962 15.8 (14.8 -16.8) 1.68 (1.53-1.84) <.001
Hypercholesterolemia 545 376 22.4 (20.2-24.8) 1.90 (1.70- 2.14) <.001
Heart diseaseb 533 342 19.4 (17.4-21.5) 1.66 (1.48- 1.87) <.001
Type 2 diabetes 514 328 19.3 (17.3-21.5) 1.66 (1.47- 1.88) <.001
Malignant neoplasmc 331 202 17.3 (15.0-19.8) 1.45 (1.25-1.68) <.001
COPD 93 67 25.4 (19.7-32.2) 2.03 (1.59-2.59) <.001
CKD 87 71 39.3 (30.7-49.6) 2.78 (2.19-3.53) <.001
Liver disease 86 42 11.4 (8.3-15.5) 1.03 (0.76-1.39) .87
Other disease 501 274 13.7 (12.1-15.4) 1.19 (1.04-1.35) .01
Time from onset
of symptoms to
ICU admission, d
<6 922 510 14.4 (13.1-15.7) 1 [Reference] NA
6-9 921 405 9.8 (8.8-10.8) 0.71 (0.62-0.81) <.001
10-14 921 411 10.2 (9.3-11.3) 0.73 (0.64-0.83) <.001
>14 921 455 13.1 (11.9-14.4) 0.84 (0.74-0.95) .006
Length of ICU stay, d
<6 994 615 22.8 (21.0-24.7) 1 [Reference] NA
6-11 993 528 14.3 (13.1-15.6) 0.59 (0.52-0.66) <.001
12-21 994 475 11.0 (10.1-12.1) 0.42 (0.38-0.48) <.001
>21 993 308 5.5 (4.9-6.1) 0.23 (0.20-0.27) <.001
Length of IMV, d
<6 634 480 37.8 (34.5-41.3) 1 [Reference] NA
6-9 634 413 21.8 (19.7-23.9) 0.52 (0.46-0.60) <.001
10-17 634 384 16.7 (15.1-18.5) 0.32 (0.37-0.43) <.001
>17 633 368 12.9 (11.6-14.3) 0.29 (0.25-0.41) <.001
Length of hospital stay, d
<15 925 837 77.7 (72.7-83.3) 1 [Reference] NA
15-27 924 565 16.9 (15.5-18.4) 0.21 (0.19-0.24) <.001
28-48 924 268 5.4 (4.7-5.9) 0.07(0.06-0.08) <.001
>48 924 58 0.9 (0.7-1.2) 0.01 (0.01-0.02) <.001
Ventilation on ICU admission
Respiratory support 76 13 3.3 (1.7-5.6) 1
NIV 350 127 7.4 (6.1-8.7) 2.36 (1.33-4.17) .003
IMV 2929 1514 13.0 (12.4-13.7) 3.77 (2.19-6.51) <.001
PaO2, mm Hg
<76 734 404 14.9 (13.5-16.5) 1 [Reference] NA
76-93 734 381 13.2 (11.9-14.6) 0.89 (0.77-1.02) .10
94-127 734 341 10.7 (9.6-11.9) 0.74 (0.64-0.85) <.001
>127 733 337 10.4 (9.3-11.6) 0.73 (0.63-0.84) <.001
(continued)
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and eTable 2 in the Supplement). A 10% increase in FiO2 on
the first day of ICU admission was associated with increased
mortality (HR, 1.24;95%CI, 1.20-1.27;P < .001),whereasa 100-
point increase in PaO2:FiO2 ratio decreasedby44% thehazard
for mortality (HR, 0.66; 95% CI, 0.61-0.71; P < .001).
Multivariable Analysis
At multivariable analysis, a 10-year increase in age (HR, 1.75;
95% CI, 1.60 -1.92) and male sex (HR, 1.57; 95% CI, 1.31-1.88)
were significantly associated with mortality (Table 2 and
eFigure 3 in the Supplement). Among comorbidities, history
of chronic obstructive pulmonary disease (HR, 1.68; 95% CI,
1.28-2.19), hypercholesterolemia (HR, 1.25; 95% CI, 1.02-
1.52), and diabetes (HR, 1.18; 95% CI, 1.01-1.39) were signifi-
cantly associatedwithmortality. No long-termuse of amedi-
cation was independently associated with mortality after
controlling for other factors (ACE inhibitors HR, 1.17 [95% CI,
0.97-1.42]; angiotensin receptorblockers [ARBs]HR, 1.05 [95%
CI, 0.85-1.29]). Decreased PEEP (HR, 1.04; 95% CI, 1.01-1.06)
and FiO2 (HR, 1.14; 95% CI, 1.10-1.19) and increased PaO2:FiO2
ratio (HR, 0.80; 95% CI, 0.74-0.87) at ICU admission were
independently associated with improved survival.
Subgroup Analyses
In the subgroup analysis of the first 1715 patients (minimum
follow-up of 73 days), the hospital mortality was 915 patients
(53.4%; 95% CI, 50.9%-55.7%), with 836 (48.7%; 95% CI,
46.4%-51.1%) dying in the ICU and 79 (4.6%; 95% CI, 3.7%-
5.7%) dying after ICU discharge. Table 3 shows the univari-
able associations of baseline characteristics and comorbidi-
ties in this subgroup. As of May 30, 2020, 14 patients (0.8%)
were still in the ICU and 127 (7.4%)were still hospitalized; the
median observation time was 80 (range, 76-112) days. The
median ICU length of stay of patientswhodied in the ICUwas
Table 1. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of 3988 Patients
With COVID-19 Admitted to the ICU in Lombardy, Italy (continued)
Characteristica
No. of
patients
(n = 3988)
No. of
deaths
(n = 1926)
Mortality rate per
1000 patient-days HR (95% CI) P value
FiO2, %
<60 751 276 7.5 (6.6-8.4) 1 [Reference] NA
60-69 751 373 11.6 (10.4-12.8) 1.46 (1.25-1.71) <.001
70-85 751 344 10.9 (9.8-12.1) 1.35 (1.16-1.59) <.001
>85 751 501 22.5 (20.6-24.6) 2.49 (2.15-2.89) <.001
PaO2:FiO2 ratio
<103 729 461 20.2 (18.4-22.1) 1 [Reference] NA
103-144 728 384 13.6 (12.2-14.9) 0.7 (0.61-0.80) <.001
145-203 729 352 11.3 (10.1-12.6) 0.6 (0.53-0.69) <.001
>203 728 259 7.1 (6.2-7.9) 0.41 (0.35-0.48) <.001
PEEP, cm H2O
<10 758 364 12.2 (10.9-13.5) 1 [Reference] NA
10-12 757 343 10.6 (9.5-11.7) 0.92 (0.79-1.06) .25
13-15 758 402 13.3 (12.1-14.7) 1.15 (1.0-1.33) .049
>15 757 412 13.3 (12.2-14.6) 1.19 (1.03-1.37) .02
Abbreviations: CKD, chronic kidney
disease; COPD, chronic obstructive
pulmonary disease;
COVID-19, coronavirus disease 2019;
FiO2, fraction of inspired oxygen;
HR, hazard ratio; ICU, intensive care
unit; IMV, invasive mechanical
ventilation; NA, not applicable;
NIV, noninvasive mechanical
ventilation; PaO2, arterial partial
pressure of oxygen; PEEP, positive
end-expiratory pressure.
a Continuous variables were divided
in quartiles and compared using the
z test from the Cox proportional
hazards regressionmodels.
b Includes cardiomyopathy and heart
failure.
c Includes active neoplasia and
neoplasia in remission.
Figure. Kaplan-Meier Analysis of Survival of Patients Admitted to the Intensive Care Unit
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10 (IQR, 5-16) days; for thosedischarged from the ICU, 15 (IQR,
8-24) days.
In the subgroup of 1643 patients with a history of hyper-
tension, long-term home treatment with ACE inhibitors,
β-blockers, statins, and diuretics was associated with higher
mortality at univariable analysis (eTable 2 in the Supple-
ment). The subgroupof 350patients initially treatedwithNIV
had lower levels of PEEP (eTable 1 in the Supplement) and
a lower hazard for mortality (HR, 0.62; 95% CI, 0.52-0.75;
P < .001) than patients treatedwith IMV. The 151 patients ini-
tially treated noninvasively and subsequently undergoing
intubation (after a median of 3 [IQR, 2-4; range, 0-15] days)
hada significantly lower chanceof survival comparedwith the
199 patients who continued to undergo NIV during the entire
ICU stay (HR, 1.69; 95%CI, 1.43-1.98; P < .001). Themortality
of the patients undergoing subsequent intubation was simi-
lar to that for the patients whowere treated withmechanical
ventilation for ICU admission (HR for IMV vs NIV fail-
ure, 1.20; 95%CI, 0.95-1.53;P = .12). eTable 1 and eFigure 4 in
the Supplement show the overall survival data for patients in
this subgroup.
Discussion
In a cohort of 3988 critically ill patients with laboratory-
confirmedSARS-CoV-2 infectionadmitted toan ICUduring the
first 2 months of the COVID-19 outbreak in Lombardy, Italy,
the estimated ICU and hospital mortality rates were 27 and
12per 1000patient-days, respectively. In the subsetof the first
1715 patients, ICU and hospital mortality were 48.8% and
53.4%, respectively. This mortality is almost double that de-
scribed in the initial report,6 in which the ICU mortality was
25.6%but 58.2%of thepatientswere still in the ICUat the end
of follow-up. These sobering statistics highlight the long ICU
stays, prolonged need for respiratory support, and highmor-
tality of COVID-19 in critically ill patients.
At the beginning of the COVID-19 outbreak in Lombardy,
many patients required ICU admission in a limited period.2,22
Hence, the ICU capacity had to be rapidly increased by estab-
lishing a network of COVID-19 ICUs in many hospitals. Expe-
rience in the treatment of patientswith acute respiratory fail-
ure and the physician-to-patient and nurse-to-patient ratios
varied widely among the centers, and this might have had an
effect on patient outcomes.23,24 Mortality of patients criti-
cally ill with COVID-19 varies significantly among the pub-
lished case series, ranging from 16% to 78%.7,8,10-12,18-20 This
wide variability can be explained by different case mixes,
different organization, availability of ICU beds among differ-
ent countries, and different lengths of follow-up. In a case
series of ICUpatients in China, 28-day ICUmortalitywas 39%
for the entire ICU population (344 patients) but reached 97%
in the subgroup of 100 patients requiring IMV.9 In the case
series of critically ill patients fromWashingtonState18 and the
Seattle region,12 71%and75%ofpatients required IMV, respec-
tively. Mortality calculated with a minimum follow-up of
12 days was 67% in Washington State; with a minimum fol-
low-up of 14 days, 50%.
Importantly, patients included in our serieswere the sick-
est patients, those treated in high-intensity (level 3) areas, as
demonstrated by the very highproportion of patients (87.3%)
undergoing IMVat ICUadmission.Manymorepatients in Italy,
notdescribedherein,havebeentreated in lower-intensity (level
2) areas, created ad hoc for the COVID-19 crisis, with ex-
tended monitoring and noninvasive respiratory support.
Our findings confirm that survival of critically ill patients
withCOVID-19 is particularly low for oldermen requiring IMV
andwithpreexistingcomorbidities.Hypertensionwasthemost
frequent comorbidity, andpatientswithhypertensionhadsig-
nificantly decreased survival. Despite this, in the multivari-
Table 2. Multivariable Cox Proportional Hazards Regression Analysis of Factors AssociatedWithMortality
Variable Category (description) Multivariable HR (95% CI) P valuea
Age in years 10-y Increments 1.75 (1.60-1.92) <.001
Men Men vs women 1.57 (1.31-1.88) <.001
Respiratory support
Spontaneous breathing vs NIV 1.81 (0.57-5.76) .32
Invasive MV vs NIV 1.24 (1.00-1.55) .052
Hypertension Yes vs no 0.99 (0.81-1.22) .93
Hypercholesterolemia Yes vs no 1.25 (1.02-1.52) .03
Heart disease Yes vs no 1.08 (0.91-1.29) .38
Type 2 diabetes Yes vs no 1.18 (1.01-1.39) .04
Malignancy Yes vs no 1.09 (0.92-1.28) .33
COPD Yes vs no 1.68 (1.28-2.19) <.001
ACE inhibitor therapy Yes vs no 1.17 (0.97-1.42) .10
ARB therapy Yes vs no 1.05 (0.85-1.29) .64
Statin Yes vs no 0.98 (0.81-1.20) .87
Diuretic Yes vs no 1.10 (0.91-1.32) .32
PEEP at admission 1-cm H2O increments 1.04 (1.01-1.06) .009
FiO2 at admission 10% Increments 1.14 (1.10-1.19) <.001
PaO2/FiO2 at admission 100-U increments 0.80 (0.74-0.87) <.001
Abbreviations: ACE,
angiotensin-converting enzyme;
ARB, angiotensin receptor blocker;
COPD, chronic obstructive pulmonary
disease; FiO2, fraction of inspired
oxygen; HR, hazard ratio;
IMV, Invasive mechanical ventilation;
MV, mechanical ventilation;
NIV, noninvasive mechanical
ventilation; PaO2, arterial partial
pressure of oxygen; PEEP, positive
end-expiratory pressure.
a Calculated using the z test from
Cox proportional hazards
regressionmodels.
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able analysis, hypertensionwasnot an independent factor as-
sociated with mortality. Conversely, a history of chronic
obstructivepulmonarydisease,hypercholesterolemia,anddia-
betes, althoughaffectingasmallerpercentageofpatients,were
independently associated with mortality.
The pathophysiology of acute respiratory failure in pa-
tientswithCOVID-19 ispoorlyunderstood. Somereports show
a significant mismatch between the degree of hypoxemia
and a relatively minor compromise of respiratory system
compliance.25 This mismatch may indicate that the optimal
setting ofmechanical ventilation in thesepatientsmaybedif-
ferent from that commonly applied in usual forms of acute
respiratory distress syndrome. Levels of PEEP applied in our
patients at ICUadmissionwerehigher than those reported for
themanagement ofmoderate to severe acute respiratory dis-
tress syndrome in the pre–COVID-19 era.26 High PEEP levels
and FiO2 and low PaO2:FiO2 ratio at ICU admission were all
independent factors associated with mortality.
Data on the effect of drugs acting on the renin-angiotensin
systemareofparticular interestbecauseACE2 is theprimaryre-
ceptor forSARS-CoV-2entry intothehostcells.17Preclinicaldata
support thehypothesis that long-termintakeofACE inhibitors,
ARBs, statins, corticosteroids,andhypoglycemicagentsmay in-
crease susceptibility to SARS-CoV-2 infection by favoring viral
replicationowingtoupregulationofACE2receptors.27-31Onthe
other hand, in patients with COVID-19, these same drugs may
theoretically improvetheclinical coursebyrebalancingthedys-
regulatedrenin-angiotensinsystemandthusreducingvasocon-
striction, inflammation, and oxidation. In a recent large case
series,mortalityofpatientswithhypertensiontakingACEinhibi-
torsorARBswashigher than thatofpatientswithhypertension
nottakingthesedrugs,butnostatisticconfirmedtheassociation
between chronic therapy with ACE inhibitors or ARBs and
mortality.10 Inourpatients, long-termtreatmentwithACEinhibi-
tors,ARBs,β-blockers, statins,diuretics, antiplateletdrugs,and
anticoagulantsbefore ICUadmissionwasassociatedwithhigher
Table 3. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of the First 1715 Patients
Variable Overalla
ICU Hospital
Death in ICU
Discharged
from ICU Still in ICU
P
valueb
Death in
hospital
Discharged
from hospital
Still in
hospital
P
valueb
All patients 1715 (100) 836 (48.7) 865 (50.4) 14 (0.8) .50 915 (53.4) 673 (39.2) 127 (7.4) .50
Men 1398/1715 (81.5) 700 (50.1) 688 (49.2) 10 (0.7)
.03
763 (54.6) 534 (38.2) 101 (7.2)
.046
Women 317/1715 (18.5) 136 (42.9) 177 (55.8) 4 (1.3) 152 (47.9) 139 (43.8) 26 (8.2)
Age, median (IQR), y 64 (56-70) 68 (62-73) 59 (52-66) 62 (52-65) <.001 68 (62-73) 58 (51-64) 62 (55-67) <.001
Comorbidities 1078/1652 (65.3) 594 (55.1) 474 (44.0) 10 (0.9) <.001 653 (60.6) 357 (33.1) 68 (6.3) <.001
None 574/1652 (34.7) 211 (36.8) 359 (62.5) 4 (0.7) <.001 228 (39.7) 292 (50.9) 54 (9.4) <.001
Hypertension 890/1703 (52.3) 500 (56.2) 382 (42.9) 8 (0.9) <.001 551 (61.9) 283 (31.8) 56 (6.3) <.001
Hypercholesterolemia 302/1652 (18.3) 191 (63.2) 110 (36.4) 1 (0.3) <.001 214 (70.9) 74 (24.5) 14 (4.6) <.001
Heart diseasec 318/1652 (19.2) 198 (62.3) 117 (36.8) 3 (0.9) <.001 224 (70.4) 76 (23.9) 18 (5.7) <.001
Diabetes 284/1652 (17.2) 182 (64.1) 100 (35.2) 2 (0.7) <.001 201 (70.8) 66 (23.2) 17 (6.0) <.001
Malignant neoplasmd 191/1652 (11.6) 113 (59.2) 78 (40.8) 0 .004 122 (63.9) 59 (30.9) 10 (5.2) .005
COPD 58/1652 (3.5) 39 (67.2) 19 (32.8) 0 .007 45 (77.6) 11 (19.0) 2 (3.4) <.001
CKD 52/1652 (3.1) 41 (78.8) 11 (21.2) 0 <.001 44 (84.6) 7 (13.5) 1 (1.9) <.001
Liver disease 45/1652 (2.7) 19 (42.2) 26 (57.8) 0 .43 21 (46.7) 20 (44.4) 1 (2.2) .79
Other disease 271/1652 (16.4) 141 (52.0) 128 (47.2) 2 (0.7) .26 155 (57.2) 98 (36.2) 18 (6.6) .21
Time from onset
of symptoms to
ICU admission,
median (IQR), d
8 (4-11) 7 (4-10) 8 (5-11) 9 (4-11) .14 7 (4-10) 8 (5-11) 8 (4-11) .07
No. of patients 1588 769 807 12 NA 844 631 113 NA
Length of ICU stay,
median (IQR), d
12 (7-20) 10 (5-16) 15 (8-24) 76 (74-80) <.001 10 (5-16) 14 (8-22) 33 (18-54) <.001
No. of patients 1711 836 861 14 NA 915 669 127 NA
Length of hospital
stay, median (IQR), d
22 (12-42) 12 (8-19) 39 (24-61) 79 (74-84) <.001 13 (8-20) 37 (23-53) 84 (79-88) <.001
No. of patients 1618 766 838 14 NA 838 658 122 NA
Length of mechanical
ventilation, median
(IQR), d
10 (6-16) 9 (5-15) 12 (7-18) 74 (73-78) <.001 9 (5-15) 11 (7-17) 20 (13-65) <.001
No. of patients 1171 787 370 14 NA 812 297 62 NA
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; ICU, intensive care unit; IQR, interquartile range; NA, not
applicable.
a Unless otherwise indicated, data are expressed as number/total number
(percentage) of patients for overall population and number (percentage) of
row total for other columns.
bCalculated for death vs discharge usingWilcoxon rank sum tests or χ2 test
according to continuous or categorical variables.
c Includes cardiomyopathy and heart failure.
d Includes active neoplasia and neoplasia in remission.
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mortality inanunadjustedanalysisonly.This findingshouldbe
interpreted with caution, because unmeasured confounders
could explain this observation, as demonstrated by the fact
that themultivariable analysis did not confirm the association
between any home therapies and increasedmortality.
Limitations
This study has several limitations. First, it is a retrospective
study based on data mainly collected by telephone primarily
for clinical purposes.Wewere able to cross-link demographic
data from other health care databases; however, this was
mainly a real-life database made for operational reasons. We
could not assess the effect of other important variables, such
asweight, bodymass index, smoking history, and respiratory
systemcompliance. Second, somevariableshavemissingdata
(eFigure 1 in the Supplement), mainly owing to the reasons
mentionedabove.Third,preexistingcomorbiditiesandchronic
medications were retrieved from the regional health system
database; therefore, the severity of the comorbidities and pa-
tientcompliancewithmedicalprescriptionscouldnotbeevalu-
ated.Moreover,wedonot have informationonhowmanypa-
tientsmaintained their long-termmedication regimensduring
the ICU stay, which may be relevant, particularly for drugs
acting on the renin-angiotensin system.
In addition, another important limitation concerns some
peculiarorganizational aspectsof intensivecare servicesof the
Italian health care system. During this crisis, we increased
thetotalcapacityofbothourhigher-intensity(level3)andlower-
intensity (level 2) areas to increaseourpotential for respiratory
support.AllpatientswithCOVID-19undergoing intubationwere
treated in level 3areasandaredescribed in this report,whereas
most patients who did not undergo intubationwere treated in
level2areas.For these reasons,webelieve thatourdataprovide
important insightsaboutpatients requiring IMVbut shouldnot
be extrapolated to the population of patients requiring other
forms of advanced noninvasive respiratory support.
Conclusions
SARS-CoV-2 represents a massive challenge for health care
systemsandthe ICUs in Italyandthroughout theworld.2Ahigh
volume of patients with the same disease required access to
intensive treatments at the same time.Until effective and spe-
cific therapies are available, supportive care is the mainstay
of treatment for critically ill patients.32,33 Providing this care
at a high-quality level for the high volume of patients to treat
is a challenge for all health care systems.
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